- Home
- TNGX vs IHRT Comparison
TNGX vs IHRT Comparison
Compare TNGX & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- IHRT
- Stock Information
- Founded
- TNGX 2014
- IHRT 1974
- Country
- TNGX United States
- IHRT United States
- Employees
- TNGX N/A
- IHRT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- IHRT Broadcasting
- Sector
- TNGX Health Care
- IHRT Consumer Discretionary
- Exchange
- TNGX Nasdaq
- IHRT Nasdaq
- Market Cap
- TNGX 317.4M
- IHRT N/A
- IPO Year
- TNGX N/A
- IHRT 2019
- Fundamental
- Price
- TNGX $1.10
- IHRT $1.21
- Analyst Decision
- TNGX Strong Buy
- IHRT Buy
- Analyst Count
- TNGX 7
- IHRT 3
- Target Price
- TNGX $12.33
- IHRT $2.83
- AVG Volume (30 Days)
- TNGX 542.7K
- IHRT 598.4K
- Earning Date
- TNGX 05-12-2025
- IHRT 05-12-2025
- Dividend Yield
- TNGX N/A
- IHRT N/A
- EPS Growth
- TNGX N/A
- IHRT N/A
- EPS
- TNGX N/A
- IHRT N/A
- Revenue
- TNGX $42,069,000.00
- IHRT $3,854,532,000.00
- Revenue This Year
- TNGX N/A
- IHRT $0.97
- Revenue Next Year
- TNGX N/A
- IHRT $5.09
- P/E Ratio
- TNGX N/A
- IHRT N/A
- Revenue Growth
- TNGX 15.17
- IHRT 2.76
- 52 Week Low
- TNGX $1.11
- IHRT $0.81
- 52 Week High
- TNGX $12.02
- IHRT $2.84
- Technical
- Relative Strength Index (RSI)
- TNGX 33.44
- IHRT 51.94
- Support Level
- TNGX $1.38
- IHRT $1.02
- Resistance Level
- TNGX $1.56
- IHRT $1.09
- Average True Range (ATR)
- TNGX 0.16
- IHRT 0.08
- MACD
- TNGX -0.01
- IHRT 0.04
- Stochastic Oscillator
- TNGX 9.90
- IHRT 86.67
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.